All In Biotech

Drug Trial Radar · NCT07859423

A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera

A Phase 2/3, Double-blind, Randomized, Placebo-Controlled, Multicenter, Efficacy, Safety, and Pharmacokinetics Study of AG-236 in Subjects With Polycythemia Vera

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 245 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

245

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Aug 2030

Study completion Aug 2032

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a Phase 2/3 study that will determine the recommended dose and dose regimen of AG-236 and evaluate the efficacy, safety, and pharmacokinetics of AG-236 in polycythemia vera (PV) by testing how well AG-236 works compared to placebo to increase the number of subjects with no phlebotomy and absence of phlebotomy eligibility over a 13-week period. In addition, the long-term effect of AG-236 on efficacy and safety will be explored in an open-label extension portion.

Conditions

  • Polycythemia Vera

Interventions

  • AG-236Drug

    SC Injection

  • PlaceboDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2 and Phase 3: Percentage of Subjects With No Phlebotomy and Absence of Phlebotomy EligibilityTime frame: Week 13 Through Week 26

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.